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ABSTRACT 
Inositol phospholipids have emerged as important key players in a wide variety of cellular 
functions. Among the seven existing inositol phospholipids, phosphatidylinositol (4,5)-
bisphosphate (PI(4,5)P2) has attracted much attention in recent years due to its important role 
in numerous cellular signaling events and regulations, which in turn impact several human 
diseases. This particular lipid is recognized in the cell by specific lipid binding domains, such 
as the Pleckstrin-homology (PH) domain, which is also employed as a tool to monitor this 
important lipid. Here, we describe the synthesis and biological characterization of a small 
molecule that mimics the PH domain as judged by its ability to bind specifically to only 
PI(4,5)P2 and effectively compete with the PH domain in vitro and in a cellular environment. 
The binding constant of this small molecule PH domain mimetic (PHDM) was determined to 
be 17.6 ± 10.1 µM, similar in potency to the PH domain. Using NIH 3T3 mouse fibroblast 
cells we demonstrated that this compound is cell permeable and able to modulate PI(4,5)P2-
dependent effects in a cellular environment such as the endocytosis of the transferrin receptor, 
loss of mitochondria as well as stress fiber formation. This highly PI(4,5)P2-specific chemical 
mimetic of a PH domain, is not only a powerful research tool, but might also be a lead 
compound in future drug developments targeting PI(4,5)P2-dependent diseases such as Lowe 
syndrome.  
 
 
 
 
INTRODUCTION 
Phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) is an important inositol phospholipid, since 
it is the precursor for several second messengers, such as phosphatidylinositol 3,4,5-
trisphosphate (PIP3) (1), diacylglycerol and 1,4,5-trisphosphate (IP3) (2). In addition, 
PI(4,5)P2 interacts with a variety of proteins such as profilin, gelsolin and α-actinin, which 
regulate the polymerization and depolymerization of actin in the cytoskeleton (3, 4). Recently, 
it has been demonstrated that PI(4,5)P2 plays an important role in the processes of exocytosis 
and endocytosis as well as the regulation of a variety of ion channels (5), suggesting that 
PI(4,5)P2 could be a key regulator of many cellular processes and diseases (6). Lowe 
syndrome for example, is caused by the mutation of the inositol-5-phosphatase OCRL, 
resulting in elevated PI(4,5)P2 levels (6,). 
Cellular levels of this lipid are maintained mainly by a balance between the 
phosphatidylinositol-monophosphate kinases (synthesis) and the counteracting 
phosphatidylinositol phosphatases (breakdown) (8, 9). Changes of PI(4,5)P2 levels are 
detected by lipid binding proteins via lipid recognition domains such as the pleckstrin 
homology domain (PH domain), which possesses sub micro-molar affinity and specificity for 
PI(4,5)P2 (10). For example, the PH domain of phospholipase C-δ1 selectively binds 
PI(4,5)P2 and its head group IP3, and thus has been applied as a tool to detect and image 
PI(4,5)P2-levels (11). Furthermore, this PH domain has also been employed as a PI(4,5)P2 
sequestering tool causing a loss of available PI(4,5)P2 levels. As demonstrated by Raucher et 
al. (4) overexpression of this PH domain resulted in the loss of actin stress fibers 
(cytoskeleton), an effect that could also be observed by overexpression of a PI(4,5)P2 specific 
phosphatase. Thus, sequestering (PH domain binding) and removal (phosphatase) of cellular 
PI(4,5)P2 affects cellular function in a similar fashion. 
Chemical alternatives to alter cellular PI(4,5)P2 concentrations do not really exist. Neomycin 
as well as poly-lysine have been proposed as tools to sequester cellular PI(4,5)P2, but their 
use are restricted due to the lack of sufficient potency and selectivity (12-14), leaving a real 
void of chemical receptors that would be able to recognize a specific inositol phosphate in a 
cellular environment. We therefore set out to design a chemical receptor that would be able to 
do this. In this paper we present the development of such a receptor and detailed studies of its 
ability to bind PI(4,5)P2 in vitro and in vivo. This is the first report on a small molecule able 
to recognize PI(4,5)P2 displaying high affinity and specificity, effectively mimicking a PH 
domain. 
 
RESULTS and DISCUSSION 
Design and development of a chemical receptor for PI(4,5)P2.  
In order to design a specific chemical receptor for PI(4,5)P2 that is capable of mimicking the 
efficacy of the equivalent biological tools (e.g. PH domain) unique recognition motifs in the 
targeted molecule have to be utilized. The head group of PI(4,5)P2 contains phosphate and 
hydroxyl functionalities (see Figure 1a) that can be exploited for this purpose. For example, it 
is well established that ureas can form complementary hydrogen bonding interactions with 
phosphates (15-18), while boronic acids have been successfully used for the molecular 
recognition of diols via the reversible formation of B-O covalent bonds (19, 20). Thus, we 
designed a chemical receptor (PHDM) that utilizes ureas and boronic acids as recognition 
motifs (see Figure 1b). In this receptor, a large central spacer was employed with the aim of 
generating two recognition pockets (each containing a urea, secondary amine and a phenyl 
boronic acid group), which allows binding to two target molecules (see Figure 1c). This 
approach of a tandem receptor has been successfully used to increase specificity and affinity 
of biological lipid recognition domains (21), a benefit desired for our chemical receptor 
designed here. 
  
The PI(4,5)P2 receptor PHDM was synthesized  via the three-step process shown in Scheme 
1. First, monoprotected amine 1 was reacted with 2-formylphenylboronic acid followed by 
reduction (with NaBH4) of the resulting imine to yield compound 2. This was followed by 
deprotection of the benzylamine to generate compound 3, which was reacted with the 4,4’-
methylenebis(phenyl isocyanate) to yield the bis-urea, bis-boronic acid target compound  
PHDM. The purity and integrity of PHDM was confirmed by 1H and 13C NMR spectroscopy, 
IR spectroscopy, mass spectrometry, HPLC separation (which showed only one trace) and 
elemental analyses (see Materials and Methods section).  
 
 
PHDM binds PI(4,5)P2  
To demonstrate the ability of the PHDM to bind PI(4,5)P2, we developed an enzyme-linked 
immunosorbant assay (ELISA) where we employed the PH domain of phospholipase C-δ1 
(PLC-δ1) to detect the available PI(4,5)P2 after exposure to increasing concentrations of 
PHDM (see Supplementary Figure 1). Since this assay provides a linear detection range in 
the presence of 80–500 nM PH domain (Figure 2b), the competition ELISA was performed 
with varying PHDM concentrations in the presence of 125 nM PH domain. As shown in 
Figure 2b, PHDM affects the binding of the PLC-δ1-PH domain to PI(4,5)P2 already at very 
low concentrations (~3 µM) demonstrating high potency (Kd = ~18 µM).  
 
 
PHDM inhibits PI(4,5)P2 phosphatases  
Next, we examined whether PHDM would be an effective inhibitor of PI(4,5)P2 metabolizing 
enzymes, since adding PHDM would lower the effective substrate (PI(4,5)P2) concentration. 
Thus, we tested the compound’s potency on three different phosphoinositide phosphatases 
(SopB, OCRL and SKIP) that preferentially hydrolyze PI(4,5)P2 (22-26). 
As shown in Figures 3a–c, increasing concentrations of PHDM inhibit all tested phosphatases 
implying that the compound is binding PI(4,5)P2 potently, effectively competing with the 
enzymes for their substrate. Interestingly, compound PHDM seems to be more potent on 
OCRL and SKIP phosphatases, although all three enzymes display similar KM towards 
PI(4,5)P2. However, this could be due to the wider substrate specificity of SopB, which also 
dephosphorylates the generated PI(4)P. To ensure that the observed reduction in phosphate 
release is not due to PHDM interacting with the enzyme, we employed 3-O-
methylfluorescein phosphate (OMFP), an artificial substrate without any structural similarity 
to inositols. By employing this substrate any interaction of PHDM with the enzymes itself 
will become obvious, since the preferred target for PHDM, the substrate PI(4,5)P2, will be 
missing. As shown in Figure 3d, no significant decrease in enzyme activity was detected in 
the presence of 50 µM PHDM as compared to the vehicle control. This proves that PHDM 
does not bind OMFP or the employed phosphatases SopB and SKIP. OCRL could not be 
tested in this manner, since it has no detectable OMFP activity. We therefore can conclude 
that the reduced phosphate release in the phosphatase assays is an effect of PHDM binding to 
the available PI(4,5)P2 substrate and not due to interactions with the three tested enzymes. 
 
 
Specificity of PHDM towards the head group of inositol lipids 
Having confirmed that PHDM is capable of inhibiting PI(4,5)P2 hydrolysis in phosphatase 
assays, we investigated the specificity of PHDM for different inositol phosphate head groups. 
Firstly, we tested PHDM’s ability to interact with the soluble head group of its target 
PI(4,5)P2, namely I(1,4,5)P3. Previous studies have shown that the PLC-δ1 PH domain, the 
biological equivalent of PHDM, binds about 8-fold more strongly to the water soluble 
I(1,4,5)P3 than PI(4,5)P2 (27). To examine the binding affinity of PHDM to I(1,4,5)P3 in 
comparison to PI(4,5)P2, we made use of the phosphatase OCRL ability to hydrolyze 
I(1,4,5)P3 as well as PI(4,5)P2 (25). Surprisingly, although I(1,4,5)P3 resembles the head 
group of PI(4,5)P2, PHDM inhibits OCRL activity better when the lipid substrate is employed 
(see Figure 4a). This implies a stronger binding of PHDM to PI(4,5)P2 than I(1,4,5)P3,which 
is in contrast to the PLC-δ1 PH domain, where I(1,4,5)P3 is clearly favored over PI(4,5)P2. 
For comparison, PHDM was also tested for its ability to bind PI(3,4,5)P3, which is generated 
in vivo by the action of PI 3-kinase on PI(4,5)P2 (1). The balance of PI(4,5)P2 and PI(3,4,5)P3 
is maintained by PTEN, which counteracts PI 3-kinase by de-phosphorylating PI(3,4,5)P3 at 
the 3’-position (28). As shown in Figure 4a, PHDM was unable to influence PTEN’s activity, 
indicating that PHDM does not bind PI(3,4,5)P3 or PTEN. In order to investigate inositol 
phosphate isomers, all naturally occurring inositol-phospholipids were subjected to a SopB 
assay, since SopB is known to hydrolyze all these lipids (22, 29). As shown in Figure 4b, the 
hydrolysis of PI(4,5)P2 by SopB is reduced in the presence of 50 µM PHDM to about 20% of 
the solvent (DMSO) control. Strikingly, all other PI-lipids were only minimally affected by 
PHDM, demonstrating that this compound has a much lower binding affinity for these related 
inositol phosphate head groups. Finally, we tested the ability of PHDM to compete with lipid-
binding proteins commonly used to detect phosphoinositides. Therefore, we modified a 
protein-lipid overlay assay, which is generally used to study binding affinities between lipids 
and PH domains (30). Normally, lipids are adsorbed onto blotting membranes, which are then 
probed with labeled proteins revealing their corresponding specificity. As shown in figure 4d, 
only the PI(4,5)P2-binding PLC-δ1 PH domain was effectively blocked at low micromolar 
concentrations, with a complete loss of PH domain binding above 10 µM PHDM. Binding of 
the Akt PH domain towards PI(3,4)P2 was only significantly affected at PHDM concentration 
of 50 µM, whereas the other lipid binding domains seem to be unaffected by up to 50 µM 
PHDM. 
 
 
Compound PHDM binds to PI(4,5)P2in NIH 3T3 mouse fibroblasts 
 
Collectively, the data presented above clearly demonstrate that PHDM is a potent and 
specific PI(4,5)P2-binding agent in vitro. In order to characterize the potency of PHDM in a 
cellular environment we first determined the cytotoxicity of PHDM on cells by using the 
MTT assay (31). As shown in Figure 5a, PHDM has no cytotoxic effect when fibroblast cells 
were treated for 2 h at concentrations as indicated. Even after prolonged exposure of 16 h, 
cell viability was still maintained at ~80% of vehicle control. 
Having confirmed that PHDM is not cytotoxic to fibroblast cells, we next investigated the 
compound’s ability to compete with the PLC-δ1 PH domain for PI(4,5)P2 in a cellular 
environment (fixed cells). NIH 3T3 cells were treated with increasing concentrations of 
PHDM, fixed and subjected to PI(4,5)P2 staining by employing the PLC-δ1 PH domain as a 
probe. As shown in Figure 5b, strong PI(4,5)P2 staining can be observed in the vehicle 
(DMSO) control, with higher fluorescence intensity at the PI(4,5)P2 rich plasma membrane 
(32). With increasing concentrations of PHDM, the PI(4,5)P2 staining decreases (>5µM 
PHDM) almost abolishing PI(4,5)P2 staining at concentrations above10 µM of PHDM. This 
data demonstrate that PHDM is capable of crossing through cellular membranes (cell 
permeable), reaching the inside of the cell where it then binds cellular PI(4,5)P2, effectively 
competing with the PH domain probe in a dose-dependent manner. In order to evaluate the 
PHDM’s ability to compete with the PLC-δ1 PH domain in vivo, we employed cells over-
expressing GFP labeled PLC-δ1 PH domains (see figure 5c). Increasing concentrations of 
PHDM correlated with increasing translocation of the PH domain (green) from the plasma 
membrane to the cytosol, with a complete loss of membrane localization achieved at PHDM 
concentrations higher than 30 µM. This process appears to start after 10 minutes of exposure 
to PHDM, being nearly completed within 30 minutes (see figure 5d). Taken together these 
data demonstrate the capability of PHDM to enter living cells, wherein this chemical 
PI(4,5)P2 receptor displaces the natural PI(4,5)P2 binding proteins (i.e. PLC-δ1 PH domain), 
which in turn suggests that PHDM is binding its intended target in living cells.  
 
PHDM inhibits PI(4,5)P2 dependant transferrin endocytosis 
Having established that PHDM binds PI(4,5)P2 in vivo, we investigated whether the PHDM-
induced changes in free PI(4,5)P2 levels would manifest in a changed cellular function.  
PI(4,5)P2 has been reported to regulate trafficking of numerous proteins to and from the 
plasma membrane that are required for receptor endocytosis such as the internalization of the 
transferrin receptor (33). Transferrin, an iron-binding glycoprotein, is transported into the cell 
by receptor-mediated endocytosis. However, depletion of plasma membrane PI(4,5)P2 causes 
a severe inhibition of the uptake of transferrin in COS-7 cells (33). We therefore investigated 
the effect of PHDM on transferrin receptor uptake in a similar fashion. As shown in Figure 6a 
(top panel), FITC-conjugated transferrin was internalized and distributed in punctuated 
structure dispersed throughout the cytoplasm (yellow color). However, in the presence of 
compound PHDM, the uptake of transferrin was drastically reduced (bottom panel; Figure 
6a). These results demonstrate that PHDM inhibits the endocytosis of the transferrin receptor 
(Figure 6b), suggesting that it also blocks PI(4,5)P2 dependent signaling and membrane 
traffic. 
 
PHDM decreases the formation of long actin stress-fibers in fibroblast cells 
Another cellular effector of PI(4,5)P2 is the cytoskeleton, which is well known to interact 
directly with this lipid (4). In particular, increases in cellular PI(4,5)P2 levels stimulate the 
formation of stress-fibers, whereas a loss of PI(4,5)P2 leads to actin depolymerization (3, 4). 
There are three possible routes to deplete cellular PI(4,5)P2: firstly, PLC-mediated hydrolysis 
to I(1,4,5)P3 and DAG; secondly, hydrolysis to PI(4)P by inositol-5-phosphatases and finally 
conversion to PI(3,4,5)P3 by PI 3-kinases. The latter pathway can be easily employed to 
disturb PI(4,5)P2 levels by activating PI 3-kinases via growth factor stimulation (e.g. insulin). 
As shown in Figure 6b, starved cells display long and densely packed stress fibers (visualized 
with phalloidin). In contrast, starved cells treated with 10 µM PHDM displayed shorter and 
less densely packed stress fibers. At the higher concentration of 50 µM actin stress fibers 
disappear nearly completely. These observations provide further evidence that PHDM is 
capable of binding to PI(4,5)P2 in vivo, which will then in turn affect cellular function. 
 
PHDM decreases the amount of mitochondria 
We recently demonstrated that mitochondrial destiny is controlled by PI(4,5)P2 (34). In 
particular, targeting the PLC-δ1 PH domain towards the outer membrane of mitochondria 
caused a gradual fragmentation in the mitochondrial network and ultimately a loss of 
mitochondria, which could be partially rescued by PKC. This implies that a PI(4,5)P2-PLC-
PKC dependent process is controlling the survival of mitochondria, which can be overcome 
by masking the available PI(4,5)P2 on the outer membrane of mitochondria. A chemical 
mimetic of the PLC-δ1 PH domain should therefore cause the loss of mitochondria, which 
indeed was observed when cells were treated with 50 µM PHDM (Figure 6c). 
Taking all these observations together, it is evident that PHDM is a potent chemical receptor 
mimicking the PLC-δ1 PH domain with respect to lipid binding. Our in vitro studies reveal 
that PHDM binds PI(4,5)P2 selectively and with high affinity. Until now, PI(4,5)P2-binding 
molecules, such as poly-lysine (35) and neomycin (36) have been used to reduce endogenous 
PI(4,5)P2 levels. However, both poly-lysine and neomycin lack specificity since both bind 
PI(4,5)P2 and other polar lipids (e.g. PtdSer) via electrostatic interactions (14). Langeland et 
al. demonstrated via binding experiments of column-immobilized poly-lysine and neomycin, 
that both compounds bind to phosphatidylserine, phosphatidylinositol and 
phosphatidylinositol monophosphate (37). These two binding agents are therefore not ideal to 
study PI(4,5)P2-dependent functions. In contrast, PHDM displays high specificity for 
PI(4,5)P2, offering a valuable and unprecedented alternative to these tools. Much of its 
specificity and potency can most likely be attributed to the well documented ability of 
boronic acid to form strong covalent bonds with cis-1,2-diols – such as the cis-1,2-diol 
present in PI(4,5)P2 (38). This type of interaction has been exploited in the past to separate 
PI(3)P from PI(4)P in thin layer chromatography(39). Since all 3-phosphorylated inositol 
lipids lack the cis-diol (2’ and 3’ hydroxyls of the inositol; see figure 1a), PHDM cannot bind 
any of these lipids with sufficient affinity. However, removing a phosphate on the inositol 
head group will weaken the interaction with the urea moiety of PHDM, which may explain 
why PHDM favors PI(4,5)P2 over PI(4)P and PI(5)P, where the cis-diols are available for 
binding. 
We have demonstrated that the high specificity of PHDM enable us to employ it as a research 
tool to study PI(4,5)P2-dependent processes in the cellular environment. Currently, altering 
cellular PI(4,5)P2 levels requires the use of chemical dimerizers (40-43), biological lipid 
recognition domains or lipid metabolizing enzymes, which are prone to interference by 
protein-protein interactions. In addition, response times are subject to biological restrains, 
since the cell has to express sufficient amounts of protein prior to any observable effects.  In 
contrast, employing PHDM allows to disturb PI(4,5)P2 levels in a  dose-dependent and 
dynamic manner. 
As a number of recent reviews pointed out, PI(4,5)P2 might be a potential therapeutic target 
in numerous human diseases (6, 44). Since the level of PI(4,5)P2 is tightly controlled by 
phosphoinositide kinases, phospholipases and phosphatases, they have been the most obvious 
targets to manipulate the level of PI(4,5)P2. 
Chemical biological research tools, like PHDM, which are custom-designed to target a 
substrate (as opposed to a protein), could unlock great potential for modulation of biological 
functions and could well gain the same momentum in drug discovery programs in future 
years as protein-targeted molecules. One particular disease that could benefit in the future 
from PHDM is the Lowe syndrome caused by the loss of the OCRL PI(4,5)P2 5-phosphatase, 
which in turn results in elevated PI(4,5)P2 levels (43). 
 
 
 
METHODS 
Chemical synthesis 
Synthesis of compound 2: Mono-Boc protected diamine 1 (0.92 g, 3.9 mmol, 1 equiv), 2-
formylphenylboronic acid (0.58 g, 3.9 mmol, 1 equiv) and 3 Å molecular sieves were 
transferred to a round-bottom flask, which was sealed and purged with nitrogen. Anhydrous 
MeOH (18.4 mL) was added followed by triethylamine (5.43 mL, 39 mmol, 10 equiv), and 
the mixture was vigorously stirred at room temperature (RT) for 2 h, then at 40 oC for another 
2h. It was then allowed to cool down to RT and after addition of solid NaBH4 (0.44 g, 11.7 
mmol, 3 equiv) it was stirred at RT for 2 h. The mixture was filtered through celite, 
concentrated under vacuum, and treated with triethylorthoformate (1.95 mL, 11.7 mmol, 3 
equiv) and a few drops of glacial acetic acid for 5–6 h at RT. The solvent was finally 
removed under vacuum and the solid was washed with petroleum ether, water and petroleum 
ether again, and left to dry first on the filter and then on a high vacuum line. This process 
afforded the desired compound 2 in 89% yield (1.28 g, 3.47 mmol) as a white solid. 1H-NMR 
(CD3OD, 3.31 ppm) δ(ppm): 1.46 (9H, singlet), 3.86 (2H, singlet), 3.97 (2H, singlet), 4.25 
(2H, singlet), 7.07 (1H, doublet, J=6.5 Hz), 7.19 (2H, m), 7.34 (2H, doublet, J=7.9 Hz), 7.42 
(2H, doublet, J=7.9 Hz), 7.48 (1H, doublet, J=6.5 Hz). 13C-NMR (CD3OD, 49.00 ppm)-
δ(ppm): 28.79, 44.73, 51.88, 54.13, 80.21, 124.25, 127.67, 128.34, 128.66, 129.79, 130.95, 
131.62, 134.86, 141.42, 142.36, 158.54. LC-MS (ESI+): Calculated (M+H) 371.21 a.m.u.; 
found 371.21 a.m.u.  
 
Synthesis of compound 3: Compound 2 (0.24 g, 0.65 mmol, 1 equiv) was transferred to a 
round-bottom flask, which was sealed and purged with nitrogen. Anhydrous CH2Cl2 (65 mL) 
was added, and the mixture was cooled to –78 oC before dropwise addition of TFA (3 mL, 40 
mmol, 61.5 equiv). The mixture was vigorously stirred at –78 oC for 1 h, then the temperature 
was allowed to slowly rise to RT over 5 h. The solvent was removed under vacuum to give 
compound 3 as a colorless oil, which was further dried on high vacuum for 24 h and used 
directly in the synthesis of 4 (see below). 1H-NMR indicated 100% boc deprotection, and 13C 
and 19F-NMR suggested the presence of some remaining TFA which, based on the obtained 
mass of 0.545 g, was determined to be 5 equiv. of TFA per molecule of 3. 1H-NMR (CD3OD, 
3.31 ppm) δ(ppm): 4.17 (2H, singlet), 4.30 (4H, singlet), 7.43 (3H, broad singlet), 7.59 (4H, 
broad singlet), 7.80 (1H, broad singlet).13C-NMR (CD3OD, 49.00 ppm)-δ(ppm): 43.73, 
51.63, 52.81, 116.75 (TFA CF3, quartet), 129.88, 130.79, 131.64, 131.82, 131.99, 132.45, 
133.27, 135.87, 136.70, 136.90, 167.09 (TFA carboxylate). LC-MS (ESI+): Calculated 
(M+H) 271.16 a.m.u.; found 271.16 a.m.u.  
 
Synthesis of compound 4: Compound 3, as its TFA salt (0.44 g, 0.52 mmol, 2 equiv), was 
transferred to a round-bottom flask, which was sealed and purged with nitrogen. Anhydrous 
DMF (6 mL) was added, followed by addition of triethylamine (3.62 mL, 26 mmol, 
100equiv) at RT, and stirring for 10 min. The excess triethylamine was used to neutralize 
residual TFA from the previous step. A solution of 4,4’-methylenebis(phenyl isocyanate) 
(0.065 g, 0.26 mmol, 1 equiv) in 1.5 mL DMF was added dropwise and the reaction was 
allowed to stir at RT for 48 h. The mixture was then concentrated under vacuum and the 
product was precipitated out of solution as a white solid by addition of water. It was filtered 
and washed extensively with water and CH2Cl2. This process afforded 60% of compound 4 
(0.123 g, 0.16 mmol). 1H-NMR (CD3OD, 3.31 ppm) δ(ppm): 3.85 (2H, singlet), 3.86 (4H, 
singlet), 3.97 (4H, singlet), 4.40 (4H, singlet), 7.08 (6H, multiplet), 7.17 (4H, multiplet), 7.26 
(4H, doublet, J=8.6 Hz), 7.38 (4H, doublet, J=8.2 Hz), 7.43 (4H, doublet, J=8.2 Hz), 7.47 
(2H, multiplet).13C-NMR (CD3OD, 49.00 ppm)-δ(ppm): 41.47, 44.18, 51.85, 54.15, 120.61, 
127.67, 128.30, 128.72, 129.82, 130.18, 131.03, 134.96, 137.25, 138.75, 141.61, 142.26, 
145.74, 148.96, 158.36. LC-MS (ESI+): Calculated (M+H) 791.39 a.m.u.; found 791.40 
a.m.u. IR (cm-1): 757, 813, 1235, 1309, 1361, 1414, 1514, 1544, 1600, 1660. Elemental 
analyses: calculated for C45H48B2N6O6·½H2O: C, 67.6; H, 6.2; N, 10.5; found: C, 67.7; H, 
6.1; N, 9.9. 
 
Biological methods 
Protein expression and purification 
All lipid-binding domains, OCRL, SKIP, SopB as well as PTEN were expressed and purified 
as GST-fusion protein. Protein expression was induced in the E. coli strain DH5α for 24 h 
using 1 mM IPTG at 23° C. After growth the cells were harvested and the pellet was stored at 
–20°C.  The harvested cells were resuspended in lysis buffer containing 50 mM Tris (pH 7.4), 
1% Triton X-100, 10 mM benzamidine hydrochloride, 100 µg mL–1 soybean trypsin inhibitor, 
1 mM 4-(2-Aminoethyl)benzenesulfonyl fluoride hydrochloride and 2 mM DTT. Lysozyme 
was added to the cell suspension at a concentration of 2 mg m–1 L and stirred for 1 h at 4°C. 
Lysis was performed by sonication, followed by centrifugation at 18000 g for 1 h at 4°C. The 
supernatant was loaded onto a glutathione sepharose column, pre-equilibrated with 50 mM 
Tris (pH 7.4), 140 mM NaCl and 2.7 mM KCl. After loading, the column was washed twice 
with 50 mM Tris (pH 7.4), 140 mM NaCl, 2.7 mM KCl and 2 mM DTT. Another two washes 
were performed using the same buffer with 500 mM NaCl. The GST-tagged protein was 
eluted using 20 mM glutathione in 50 mM Tris (pH 7.4), 250 mM NaCl, 20% (v/v) glycerol 
and 2 mM DTT. Protein integrity was confirmed by Western blotting using GST-antibody. 
Protein concentration was determined using Bradford assay. 
 
Protein-lipid overlay assay 
Inositol phospholipids were pre-incubated with increasing concentration of PHDM or solvent 
control for 20 min. 50 pmol of inositol-phospholipid was spotted onto a nitrocellulose 
membrane followed by blocking with 0.25% (w/v) fatty-acid free bovine serum albumin 
(BSA) in 50 mM TRIS buffer, pH 7.4. Membrane was washed 3 times with 50 mM TRIS pH 
7.4 containing 150 nM sodium chloride and 0.1% (v/v) Tween 20 (TBST) for 5 min each. 
Membranes were then incubated with the corresponding lipid-binding domain in blocking 
buffer. The concentrations of lipid-binding domains were optimized to insure a dose-
dependent detection of bound lipid. The following concentrations of lipid-binding domains 
were used: 25 nM PLC-δ1 PH domain, 5 nM FYVE domain, 50 nM FAPP1 domain, 25 nM 
Akt PH domain and 50 nM GRP1 PH domain.  After washing with TBST for 1 hour bound 
PH domain was visualized using a GST-antibody and horseradish-peroxidase-conjugated 
secondary antibody with washing of 1 hour in TBST in between. Membrane was then probe 
using western blotting detection reagent. 
Phosphatase enzyme assay with inositol phospholipid substrates 
Inositol phospholipids were presented as mixed micelles with octyl glucoside. Therefore, 
lipids were sonicated with 1% (v/v) octyl glucoside in assay buffer (100 mM Tris, pH 7.4) for 
10 min and added to the assay with a final concentration of 0.25% (v/v) octyl glucoside. 
Phosphatase activities were measured in 100 mM Tris, pH 7.4 and 4 mM MgCl2 at 37˚C for 
30 min. Reactions were terminated after 30 min by adding 2.25 volume of color reagent (5 
mM malachite green oxalate, 17 mM ammonium heptamolybdate, 77 mM bismuth citrate and 
1.7 M HCl) to quantify amount of phosphate release. The mixture was allowed to develop for 
10 min at RT, and the absorbance was read at 625 nm. All enzyme assays were performed in 
a 96-well microtiter plate.  
Phosphatase enzyme assay with OMFP as substrate 
3-O-Methylfluorescein phosphate cyclohexylammonium salt (OMFP) was dissolved into 
anhydrous DMSO to a concentration of 20 mM and then further diluted with 1 % (v/v) 
DMSO to the tested concentrations.  Assays were performed in 100 mM TRIS (pH 7.4) 
containing 4 mM MgCl2. Reactions were initialized by adding OMFP to the enzyme-buffer 
mixture. The hydrolysis of OMFP to OMF was monitored by measuring the change of 
fluorescence units in a 96-well microtiter plate (excitation at 485 nm and emission at 525 nm) 
using a Varian fluorescence spectrophotometer. 
Cytotoxicity assay 
NIH 3T3 cells were seeded into a 96-well plate at a concentration of ~8,000 cells per well 
and incubated at 37 °C for 16 h. Cells were treated with PHDM at concentrations between 5 
µM and 50 µM for 2 h or 16 h, respectively at 37 °C (total volume of 100 µL). After 2 h or 
16 h, 20 µL of a 5 mg mL–1 MTT solution was added to each well and the mixture was 
incubated for a further 4 h at 37 °C. The media were removed carefully, 150 µL of 4 mM HCl 
in isopropyl alcohol was added to each well, and the mixture was incubated at room 
temperature for 15 min on an orbital shaker. The formation of formazan by viable cells was 
measured using a spectrophotometer at 590 nm. 
Detection of cellular PI(4,5)P2 via immunofluorescence  
Detection of cellular PI(4,5)P2 was performed according to the methods previously described 
with some modifications(45). NIH 3T3 mouse fibroblast were grown in Dulbecco’s modiﬁed 
Eagle’s medium (DMEM) supplemented with 10% bovine calf serum in an atmosphere of 
5% CO2 at 37˚C. Cells were seeded onto glass coverslips in a 24-well plate and starved 
overnight in serum-free DMEM. Cells were incubated with PHDM or DMSO and fixed with 
4 % paraformaldehyde (PFA) for 15 min at RT. After 3 washes with 50 mM ammonium 
chloride in phosphate buffer saline (PBS), plate was chilled on ice for 20 min, prior to 
permeabilization with 0.5% (w/v) saponin in PBS for 30 min. Coverslips were block with 3% 
fatty acid free bovine serum albumin (BSA), followed by 3 washes with NH4Cl/PBS. 100 nM 
of GST-tagged PLC-δ1 PH domain in blocking bluffer were added to the cells and incubate 
for 1 hour on ice. Cells were washed three times with NH4Cl/PBS and an Alexa 488-
conjugated GST-specific antibody was added and incubated for 1 hour at RT. After 3 washes 
with PBS, cells were fixed with 2% PFA for 10 min at RT. Cells were washed 3 times with 
PBS and then treated with 300 nM 4’,6-diamidino-2-phenylindole (DAPI) for nuclear 
counterstaining. Thoroughly washed coverslips were mounted onto glass slides using Mowiol 
supplemented with 0.6% (w/v) 1,4-diazabicyclo-[2.2.2]octane. Fluorescence microscopy was 
performed using a Nikon TE 2000 ﬂuorescence microscope. Filters used in the ﬂuorescence 
experiments were band pass for DAPI, FITC and TRITC with excitation wavelength of (nm) 
340–380, 465–495 and 540–580, respectively, and with emission wavelength of (nm) 435–
485, 515–555 and 572–605, respectively. Images were digitally acquired with a CCD camera 
(Hamamatsu) for each ﬂuorophore separately and processed using IPLab software v 3.65a 
and ImageJ. 
Transferrin uptake assay, detection of actin stress fibers and mitochondria staining 
NIH 3T3 cells were grown on coverslips in 10% bovine calf serum DMEM for 24 h. Cells 
were incubated with compound PHDM at concentrations indicated or solvent control 
respectively for 30 min in serum free DMEM. Alexa 488-human transferrin conjugate was 
added in serum free DMEM at a final concentration of 5 µg ml–1 and any excess was washed 
away with acidic PBS and subsequently neutral PBS (after 15min) . For stress fibers 
detection cells were incubated with FITC-conjugated phalloidin for 1 hour at RT. For 
mitochondria staining, cells were treated with MitoTracker Red 580 (Invitrogen) according to 
manufacturer’s protocol. Cells were PFA fixed and nuclei were DAPI stained. The coverslips 
were mounted in MOWIOL mounting medium and subjected to fluorescence microscopy as 
described above. 
Fluorescence time-lapse microscopy 
NIH 3T3 cells transfected with GFP-PLC-δ1 PH domain were observed under a Nikon TE 
2000 ﬂuorescence microscope using a 100× Fluor oil lens. Images were taken every 1 min 
after addition of PHDM or vehicle control. 
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 Figure 1. (a) Chemical structure of D-myo-inostiol (1,4,5). (b) Chemical structure of receptor  
(PHDM) with diol and phosphate-binding groups; a large and relatively rigid spacer allows 
for two separate PI(4,5)P2 binding pockets to be present in the same molecule. (c) Space-fill 
computer model of the receptor under study (PHDM) binding two different PI(4,5)P2 
molecules (the receptor is shown in black and the PI(4,5)P2 molecules in white). Hydrogens 
have been omitted for clarity; the aliphatic chain attached to PI(4,5)P2 was substituted for 
shorter propyl groups to simplify the calculations. Optimization was carried out by molecular 
mechanics first, MM2 force field, followed by DFT calculations at the B3LYP/6-31G level 
using Gaussian. 
 
  
Scheme 1. Reaction scheme for the synthesis of PHDM. 
 Figure 2. (a) Immobilized PI(4,5)P2 was assayed in the dependence of PH domain 
concentration. (b) Competition ELISA for determination of dissociation constant of PHDM. 
Displacement curve is shown as a function of PHDM concentration. The Kd is determined to 
be 17.6 ± 10.1 µM. Data presented are the mean ± the standard deviation of at least three 
independent experiments performed in triplicates (n=3). 
 Figures 3. (a–c) PI(4,5)P2 hydrolyzing phosphatases SopB, OCRL and SKIP were used in 
dose response studies of compound PHDM. PI(4,5)P2 was presented in octyl glucoside mixed 
micelles at a substrate concentration of 20 µM which is around the KM value reported for 
these three enzymes (SKIP and OCRL: 23 µM (24), SopB: 28 µM). Phosphatase activity was 
determined as described earlier (24). The IC50s were determined to be: SopB: 21.6 ± 6.5 µM, 
OCRL: 7.0 ± 0.6 µM, SKIP: 6.9 ± 0.7 µM. (d) SopB and SKIP in phosphatase assay with 
artificial substrate 3-O-methylﬂuorescein phosphate (OMFP) with and without PHDM. 
PHDM was used at a concentration of 50 µM with 150 µM OMFP substrate. OCRL could 
not be tested in this manner, since it has no detectable OMFP activity.  
 Figure 4 (a) Head group specificity of PHDM studied with OCRL/I(1,4,5)P3 and PI(4,5)P2 
and PTEN/PI(3,4,5)P3. The remaining phosphatase activities in the presence of 20 µM 
PHDM compared to control are shown. All 3 substrates were used at a concentration of 20 
µM. (b) Head group specificity of PHDM towards all 7 inositol phospholipids in phosphatase 
assays with SopB. All tested inositol-phospholipids contain the same fatty acid composition 
(diC16, palmitoyl) to ensure comparison of PHDM specificity based only on the inositol head 
group. Lipids were presented in octyl glucoside mixed micelles at concentrations of 20 µM. 
PHDM was used at 50 µM and the remaining SopB activities are presented as percentage of 
solvent control (no PHDM). The amount of SopB employed were adjusted for each inositol-
phospholipid to ensure similar turnover rates (for details see supplementary figure 2). (c) 
Protein-lipid overlay assay in the presence of PHDM. Inositol phospholipids were pre-
incubated with increasing concentrations of PHDM followed by incubation with GST-tagged 
lipid-binding domains. Bound domains were visualized with anti-GST and horseradish 
peroxidase antibodies. Results shown are representative of 3 independent experiments. 
 Figure 5. (a) Cytotoxicity of compound PHDM studied using MTT assay. NIH 3T3 cells 
were incubated with PHDM for 2 h and 16 h at concentrations as indicated. The results are 
presented as the mean ± the standard deviation of 4 independent experiments performed in 
triplicates (n = 4). (b) Immunofluorescence of bound PLC-δ1 PH domain in the presence of 
PHDM. Starved NIH 3T3 fibroblast were treated with concentrations of PHDM as indicated, 
PFA-fixed and incubated with GST-tagged PLC-δ1 PH domain, followed by incubation with 
Alexa 488-conjugated GST-specific antibody. Green channel: PI(4,5)P2 staining; blue: DAPI 
counter stain. Scale bar: top panel: 100 µm; bottom panel: 10 µm. Quantification of bound 
PH domain from fluorescence imaging using ImageJ are presented in the bar chart on the 
right side. Data for the quantification was obtained from 6 independent experiments (n = 6) 
over a minimum of 180 cells. (c) NIH 3T3 cells were transiently transfected with an 
expression vector encoding GFP-tagged PLC-δ1 PH domain. 24 hours after tranfection, cells 
were treated with PHDM at indicated concentrations, PFA-fixed and imaged. Scale bar: 10 
µm. Quantification of cells displaying predominantly cytosolic PLC-δ1 PH domain staining 
are presented in the bar chart on the bottom. Data for the quantification was obtained from 3 
independent experiments (n = 3) counting a total of 120 cells. (d) Live cells time-lapse study 
showing the release of GFP-tagged PLC-δ1 PH domain into the cytosol upon the addition of 
40 µM PHDM. Scale bar: 10 µm. Results shown are representative of 8 independent 
experiments. (e) Control experiment to (d) where the solvent vehicle (DMSO) was added to 
the cells instead of PHDM. Scale bar: 10 µm. Results shown are representative of 4 
independent experiments.  
 Figure 6. (a) Transferrin uptake in the presence of PHDM. NIH 3T3 cells were treated with 50 µM 
PHDM or solvent control for 30 min followed by incubation with Alexa 488-conjugated human 
transferrin for 15 min. Right panel: DAPI (blue); middle panel: transferrin (yellow); left panel:merged 
images. Scale bar: 10 µm. Quantification of the transferrin uptake assay was performed using ImageJ 
software (4 independent experiments over a minimum of 20 cells), which is presented in the bar chart 
on the right side. (b) PHDM induces de-polymerization of stress fibers. Stress fiber formation was 
monitored with FITC-conjugated phalloidin staining.  NIH 3T3 cells were serum starved for 16 hours 
followed by treatment as indicated. Images shown are representative of 5 independent experiments (n 
=5). Scale bar: 10 µm. (c) PHDM reduces the size of mitochondria in NIH 3T3 cells. Cells were 
treated with 50 µM of PHDM for 30 min followed by staining with MitoTracker probe for 15 min. 
Cells were fixed, counterstained with DAPI (blue) and examined by fluorescence microscopy. Scale 
bar: 10 µm. Statistical analysis of mitochondria fluorescence using particle count measurements in 
randomly chosen ﬂuorescence positive cells (see bar chart on the right side) were performed using 
ImageJ over a minimum of 280 cells from 3 independent experiments (n=3). Scale bar: 10 µm. 
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Supplementary Figure 1. Schematic presentation of the ELISA competition assay. Vesicles 
containing 99% 1,2-dioleoyl-glycero-3-phosphocholine (DOPC) and 1% PI(4,5)P2 were 
immobilized onto a 96-well microtiterplate. Compound PHDM competes with GST-tagged 
PLC-δ1 PH domain for binding to PI(4,5)P2. Bound PH domain was quantified using anti-
GST antibody and alkaline phosphatase-conjugated secondary antibody. P-nitrophenyl 
phosphate (substrate) was added and the absorbance at A = 425 nm was recorded. 
 
METHOD 
ELISA binding assay 
Vesicles containing 99% 1,2-dioleoyl-glycero-3-phosphocholine (DOPC) and 1% PI(4,5)P2 
were prepared by sonication for 10 min at RT. A solution containing 0.01 µM lipids were 
added to a 96-well micro-titer plate and incubated at RT for 2 h. Wells were washes three 
times with Tris buffer saline (TBS) followed by blocking with 2 % (w/v) goat serum in TBS 
for 2 h at RT. Wells were washes three times and incubated with either PHDM and/or PH 
domain for 1 h. After 3 washes with TBS, a GST-antibody (mouse) solution in TBS were 
added to the wells and incubated at RT for 1 h. Again, wells were washes three times with 
TBS followed by incubation with an alkaline phosphatase-conjugated anti-mouse antibody at 
RT for 1 h. Cells were washes three times with TBS and substrate solution containing para-
nitrophenyl phosphate was added. The reaction was monitored with a 96-well ELISA plate 
reader at an absorbance of A = 405 nm. 
 
Supplementary Figure 2. SopB amount employed for each lipid in Figure 4b was adjusted 
in order to achieve similar turnover rates, thus compensating for SopB’s substrate specificity 
differences. The amount of SopB employed for each lipid is given above the bar chart relative 
to PI(4,5)P2. All data presented are the mean ± the standard deviation of at least three 
independent experiments performed in triplicates. 
 
 
 
 
Supplementary Figure 3. Addition of PHDM releases GFP-tagged PLC-δ1 PH domain into 
the cytosol. NIH 3T3 cells were transiently transfected with an expression vector encoding 
GFP-tagged PLC-δ1 PH domain. 24 hours after tranfection, cells were treated with PHDM 
and imaged using time-lapse fluorescence microscopy.  
	  
 
